
CLAIMS


1. Use of a RXR agonist of Formula I,



(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof in the preparation of a medicament, for treating a patient with $Her2^+$ cancer, wherein the patient has received, is receiving, or is scheduled to receive a Her2-targeted therapeutic agent.

2. Use of a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, in the preparation of a medicament for treating a patient with $Her2^+$ cancer, wherein said RXR agonist is to be used in combination with a Her2-targeted therapeutic agent.

3. The use of any one of claims 1 or 2, wherein thyroid hormone is to be administered in conjunction with the RXR agonist.

4. The use of claim 3, wherein the thyroid hormone is thyroxine.

5. The use of any one of claims 1-4, wherein the RXR agonist is a compound of Formula II



(Formula II).

6. The use of any one of claims 1-5 wherein an anti-Her2 therapeutic antibody is to be further administered.

7. The use of claim 6, wherein the therapeutic antibody is trastuzumab or pertuzumab.


8. The use of any one of claims 1-5, wherein an antibody-drug conjugate is to be further administered, wherein the antibody is an anti-Her2 antibody.

9. The use of claim 8, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.

10. The use of any one of claims 1-9, wherein a Her2 kinase inhibitor is to be further administered.

11. The use of claim 10, wherein the Her2 kinase inhibitor is lapatinib or neratinib.

12. A combination comprising a Her2-targeted therapeutic agent and a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof.

13. The combination of claim 12, further comprising thyroid hormone.

14. The combination of claim 12, wherein the RXR agonist is a compound of Formula II



(Formula II).

15. The combination of claim 12, wherein the Her2-targeted therapeutic agent

comprises an anti-Her2 therapeutic antibody selected from trastuzumab or pertuzumab.

16. The combination of claim 12, wherein the Her2-targeted therapeutic agent comprises an antibody-drug conjugate wherein the antibody is an anti-Her2 antibody comprising ado-trastuzumab emtansine.

17. The combination of claim 12, wherein the Her2-targeted therapeutic agent comprises a Her2 kinase inhibitor selected from lapatinib or neratinib.